Deep learning radiomics-based prediction of distant metastasis in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy: A multicentre study

• Main Authors: Xiangyu Liu, Dafu Zhang, Zhenyu Liu, Zhenhui Li, Peiyi Xie, Kai Sun, Wei Wei, Weixing Dai, Zhenchao Tang, Yingying Ding, Guoxiang Cai, Tong Tong, Xiaochun Meng, Jie Tian
• Format: Article
• Language: English
• Published: Elsevier 2021-07-01
• Series: EBioMedicine
• Subjects: Locally advanced rectal cancer; Distant metastasis; Neoadjuvant chemoradiotherapy; Deep learning radiomics; Magnetic resonance imaging
• Online Access: http://www.sciencedirect.com/science/article/pii/S2352396421002358

Background: Accurate predictions of distant metastasis (DM) in locally advanced rectal cancer (LARC) patients receiving neoadjuvant chemoradiotherapy (nCRT) are helpful in developing appropriate treatment plans. This study aimed to perform DM prediction through deep learning radiomics. Methods: We retrospectively sampled 235 patients receiving nCRT with the minimum 36 months’ postoperative follow-up from three hospitals. Through transfer learning, a deep learning radiomic signature (DLRS) based on multiparametric magnetic resonance imaging (MRI) was constructed. A nomogram was established integrating deep MRI information and clinicopathologic factors for better prediction. Harrell's concordance index (C-index) and time-dependent receiver operating characteristic (ROC) were used as performance metrics. Furthermore, the risk of DM in patients with different response to nCRT was evaluated with the nomogram. Findings: DLRS performed well in DM prediction, with a C-index of 0·747 and an area under curve (AUC) at three years of 0·894 in the validation cohort. The performance of nomogram was better, with a C-index of 0·775. In addition, the nomogram could stratify patients with different responses to nCRT into high- and low-risk groups of DM (P < 0·05). Interpretation: MRI-based deep learning radiomics had potential in predicting the DM of LARC patients receiving nCRT and could help evaluate the risk of DM in patients who have different responses to nCRT. Funding: The funding bodies that contributed to this study are listed in the Acknowledgements section.